Innova Captab places ₹400 cr bid for Sharon Bio-Medicine | Mint
Active Stocks
Mon Feb 26 2024 15:59:59
  1. Tata Steel share price
  2. 142.60 -1.99%
  1. Power Grid Corporation Of India share price
  2. 287.75 1.97%
  1. HDFC Bank share price
  2. 1,422.25 0.10%
  1. ITC share price
  2. 409.20 -0.58%
  1. State Bank Of India share price
  2. 759.00 -0.05%
Business News/ Companies / News/  Innova Captab places 400 cr bid for Sharon Bio-Medicine

Innova Captab places ₹400 cr bid for Sharon Bio-Medicine

Immediate payment of ₹350 crore, and the rest ₹50 crore to be paid over the next one year
  • This is the second round of the insolvency proceedings of Sharon Bio-Medicine
  • Sharon Bio-Medicine develops and manufactures pharmaceutical intermediates, actives, and finished dosages..Premium
    Sharon Bio-Medicine develops and manufactures pharmaceutical intermediates, actives, and finished dosages..

    MUMBAI : Homegrown pharma company Innova Captab Ltd has placed a bid of 400 crore to acquire debt-laden Sharon Bio-Medicine Ltd in an ongoing insolvency resolution process, two people aware of the development said.

    This is the second round of the insolvency proceedings of Sharon Bio-Medicine. In the first round, Peter Beck und Partner Vermoegensverwaltung (PBP), the successful bidder, had failed to implement its resolution plan.

    PBP had made an offer of 230 crore to secured creditors, against claims of 702 crore, the people cited above said on the condition of anonymity.

    “Innova Captab has offered a bid of 400 crore, which includes an immediate payment of 350 crore and the balance 50 crore over one year. The second round of the resolution process as per NCLT (National Company Law Tribunal) directive needs to be completed by 16 September," one of the two people said.

    A few other pharma companies have also submitted bids to acquire Sharon Bio-Medicine, the person said, adding that the filing deadline is 22 August.

    On 18 August, The Economic Times reported that Piramal Pharma and Cadila Pharmaceuticals have shown interest in the company.

    Sharon Bio-Medicine develops and manufactures pharmaceutical intermediates, actives, and finished dosages, besides generic alternatives for new drugs. It posted a loss of 1.1 crore on a revenue of 37.83 crore in the June quarter.

    An email query sent to Innova Captab did not elicit any response till press time.

    Innova Captab is an integrated pharmaceutical company with a presence in research and development, manufacturing and drug distribution.

    Innova Captab is planning to go public and has filed its draft prospectus on 29 June for an initial share sale that will see the company raise 400 crore in equity and an offer for sale of 9.6 million shares by existing shareholders.

    The proposed initial public offering (IPO) is likely to be for 700-900 crore.

    Mint had reported that the company raised 50 crore at a pre-IPO round from UTI AMC backed UTI Capital at a valuation of 2,400 crore.

    Innova Captab was founded as a partnership company in 2005. It has two WHO-GMP (World Health Organization’s Good Manufacturing Practices) certified manufacturing facilities in Baddi and a research and development facility approved by the Council of Scientific and Industrial Research.

    It runs a contract development and manufacturing organization business providing manufacturing services to Indian pharmaceutical companies, besides a domestic-branded generics business and an international-branded generics business.

    Innova counts pharma majors such as Ajanta Pharma, Mankind Pharma, Sun Pharma, Abbott Pharma, Cipla, Glenmark Pharma, Lupin and Emcure Pharma as its customers, offering contract research and manufacturing. On the generics side, it has a portfolio of more than 400 products sold via 3,400-plus stockists and distributors covering around 96,000 retail touchpoints.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Swaraj Singh Dhanjal
    " Based in Mumbai, Swaraj Singh Dhanjal is responsible for Mint’s corporate news coverage. For the past eight years he has been writing on the biggest deals in private equity, venture capital, IPO market and corporate mergers and acquisitions. An engineer and an MBA, he started his journalism career in 2014 with Mint. "
    Catch all the Corporate news and Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates & Live Business News.
    More Less
    Published: 30 Aug 2022, 11:26 PM IST
    Next Story footLogo
    Recommended For You
    Switch to the Mint app for fast and personalized news - Get App